Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Crohn's Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

21 recruiting trials for Crohn's Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 21 Crohn's Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 60% (6 studies); the largest phase groups are Phase 3: 6, Phase 4: 2, Phase 2: 1, Phase 1 / Phase 2: 1.

Research is led by AbbVie (3), Takeda (3), Brain Inflammation Collaborative (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Risankizumab (drug, 2 trials), followed by Upadacitinib, Vedolizumab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
21
Total Trials
21
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Track Crohn's Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04806620

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from...

Sponsor: Brain Inflammation CollaborativeEnrolling: 100001 location
RECRUITINGNCT06512597

Behavioral Therapy for Crohn's Disease

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 1702 locations
RECRUITINGPhase 3NCT05995353

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves...

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess...

Sponsor: AbbVieEnrolling: 11020 locations
RECRUITINGNCT06780683

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD), which encompasses ulcerative Colitis (UC) and Crohn's Disease (CD), has seen significant improvements in patient outcomes with biologic...

Sponsor: Xiang GaoEnrolling: 1746 locations
RECRUITINGPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's...

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 120020 locations
RECRUITINGNCT05683730

Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. CD is a common inflammatory bowel disease (IBD), frequent (150,000 patients in France...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 1741 location
RECRUITINGNCT05113095

A Survey of Darvadstrocel in People With Crohn's Disease

This study is a survey in Japan of Darvadstrocel injection used to treat Crohn's disease people with complicated anal fistula. The study sponsor will not be involved in how the...

Sponsor: TakedaEnrolling: 2751 location
RECRUITINGPhase 4NCT06045754

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab...

Sponsor: TakedaEnrolling: 10020 locations
RECRUITINGPhase 2NCT07113522

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study...

Sponsor: Mirador Therapeutics, Inc.Enrolling: 14020 locations
RECRUITINGNCT07377188

Pregnancy and Inflammatory Bowel Disease

Inflammatory Bowel disease, including Crohn's disease and Ulcerative Colitis, are chronic diseases. Diagnosis is most often done in women of childbearing age. IBD can have and...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 9451 location
RECRUITINGPhase 3NCT06332534

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to...

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many...

Sponsor: AbbVieEnrolling: 11020 locations
RECRUITINGNCT07504510

Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease

The goal of this observational study is to evaluate the effectiveness and safety of exclusive enteral nutrition (EEN) in adults with active Crohn's disease (CD), particularly in...

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen UniversityEnrolling: 3001 location
RECRUITINGNCT01731665

Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.

The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of...

Sponsor: Asan Medical CenterEnrolling: 20001 location
RECRUITINGPhase 1 / Phase 2NCT00692939

Autologous Stem Cell Transplantation for Crohn's Disease

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood...

Sponsor: Paul SzabolcsEnrolling: 202 locations
RECRUITINGNCT06006039

The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient...

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Enrolling: 402 locations
RECRUITINGNCT06023030

An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants...

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating...

Sponsor: AbbVieEnrolling: 24020 locations
RECRUITINGNCT07242248

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's...

The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the...

Sponsor: Janssen-Cilag Ltd.Enrolling: 2201 location
RECRUITINGPhase 3NCT04777656

Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric...

This research is a multicenter French randomized and single blinded phase III clinical trial evaluating two treatment strategies among Crohn's disease (CD) patients. The main...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1204 locations
RECRUITINGPhase 3NCT06405087

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease...

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time....

Sponsor: TakedaEnrolling: 7020 locations
RECRUITINGPhase 4NCT06180382

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of...

A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor...

Sponsor: Centre Hospitalier Universitaire de Saint EtienneEnrolling: 22012 locations
RECRUITINGPhase 3NCT06937099

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and...

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult...

Sponsor: Eli Lilly and CompanyEnrolling: 29020 locations

Frequently Asked Questions

There are currently 21 clinical trials for Crohn's Disease, with 21 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Crohn's Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Crohn's Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.